Creutzfeldt-Jakob disease (CJD) is the reason instrument reprocessing has an exception built into it: the infectious agent is a misfolded protein that survives the temperatures, chemicals and contact times that reliably destroy bacteria, fungi, mycobacteria and viruses. Canadian guidance answers the question most reprocessing rooms actually face — not "how do I sterilize a prion", but "which instruments, which tissues, and which of four actions applies" — through a decision path published by the Public Health Agency of Canada, and United States guidance routes to the same underlying decontamination methods through the Centers for Disease Control and Prevention. This article sets the two side by side, clause by clause, and shows where the Canadian path is more granular than the sentence most English-language summaries stop at.
| Quick facts | Detail |
|---|---|
| Canadian instrument-handling source | Public Health Agency of Canada, Classic Creutzfeldt-Jakob Disease in Canada: Quick Reference Guide, September 2007, developed from the 2002 CJD infection control guideline |
| Canadian decontamination methods | Four-step CJD decontamination, with two accepted substitutions |
| United States source | CDC, Infection Control for CJD, health care provider guidance |
| International decontamination annex | WHO infection control guidelines for transmissible spongiform encephalopathies, published as WHO/CDS/CSR/APH/2000.3 |
| Canadian provincial layer | Ontario Public Health Standards infectious diseases protocol, appendix for CJD, all types |
| Actions available in the Canadian path | Discard, CJD decontamination and reuse, routine reprocessing and reuse, routine reprocessing and quarantine |
Why is a normal steam cycle not treated as sufficient?
Prions are not organisms, so the usual inactivation logic does not transfer. The Canadian quick reference guide is direct about the limits of the cycle most clinics run: it states that the working group did not believe, on the evidence, that autoclaving at 134 °C for 18 minutes by itself suffices to deactivate prions, and therefore did not recommend that as a routine procedure to prevent CJD transmission. That single sentence is the reason the guidance does not tell a facility to run a longer cycle and move on.
United States guidance frames the same uncertainty from the evidence side. The CDC notes that inactivation studies have not rigorously evaluated the effectiveness of the actual cleaning and reprocessing methods used in healthcare facilities, and that the recommendations are derived primarily from in vitro inactivation studies using brain tissue or tissue homogenates — both of which pose extreme challenges to any sterilization process. In other words, the recommended methods are conservative by design, because the supporting experiments are harder on the agent than a normal instrument load is.
The other half of the answer is about the instrument, not the cycle. Where instruments contact high-infectivity tissue, single-use instruments are strongly recommended, and where single-use is not available the maximum-safety option is destruction, with decontamination as the fallback when destruction is not practical.
Which tissues decide the answer?
Everything downstream depends on which tissue the instrument contacted. Canada classifies human tissue into three categories, and the classification was updated in the quick reference guide using the WHO tissue-infectivity work, with a specific change worth knowing.
| Category | Canadian classification (PHAC, 2007) | Practical effect |
|---|---|---|
| High infectivity | Brain; dura mater; pituitary gland; posterior eye (optic nerve and retina); spinal cord and spinal ganglia; trigeminal ganglia | Drives the discard decision for confirmed cases and the quarantine decision for suspected cases |
| Low infectivity | Cerebrospinal fluid; cornea; kidney; liver; lung; lymph nodes; placenta; spleen | Reprocessing tolerates CJD decontamination or quarantine rather than automatic destruction |
| No detected infectivity | Includes dental pulp, gingival tissue, skin, heart, skeletal muscle, peripheral nerves, urine, saliva, sweat, tears, breast milk, blood and bone marrow | Routine reprocessing and reuse applies |
Two footnotes in the Canadian document carry most of the operational weight. The first is that cerebrospinal fluid is classified as a low-infectivity tissue, but contact with cerebrospinal fluid necessarily implies contact with high-infectivity tissue, so it is managed as a high-infectivity tissue or fluid for infection prevention and control purposes. The second is that the update moved dental pulp from low infectivity to no detected infectivity, based on experiments that did not detect abnormal prion protein in dental pulp of patients with human transmissible spongiform encephalopathies, and reclassified the trigeminal and spinal ganglia as high infectivity.
The WHO guideline reaches the same practical conclusion with a shorter list — brain, spinal cord and eye as high infectivity, with cerebrospinal fluid and several non-central-nervous-system organs as low infectivity — and then adds the same exception, that instruments contaminated by cerebrospinal fluid should be handled in the same manner as those contacting high-infectivity tissues.
Which instruments are "high risk", and what is the test?
This is the question the phrase "requires special handling" usually dodges. In the Canadian path, risk is not a property of the instrument. It is a function of two inputs: the patient's status as a potential CJD transmitter, and the infectivity category of the tissue the instrument contacted. The instrument itself only matters in the third step, where the guidance asks whether it can survive the decontamination it would otherwise receive.
| Patient status | Tissue contacted | Action in the Canadian decision path |
|---|---|---|
| Confirmed CJD | High infectivity | Discard |
| Confirmed CJD | Low infectivity | CJD decontaminate and reuse if the instrument tolerates it; otherwise discard |
| Confirmed CJD | No detected infectivity | Routine reprocessing and reuse |
| Suspected CJD | High infectivity | Routine reprocessing separately, then quarantine; discard if CJD is not excluded |
| Suspected CJD | Low infectivity | CJD decontaminate and reuse if tolerated; otherwise routine reprocess separately and quarantine |
| Asymptomatic carrier of a genetic TSE | High infectivity | Discard |
| At-risk patient, any tissue | Any | Routine reprocessing and reuse |
The instrument-tolerance test is blunt and it is written into the guidance. Instruments made of high-quality stainless steel can tolerate CJD decontamination using sodium hydroxide. Instruments that contain plastic or electronic components, such as bronchoscopes, cannot. Instruments that contain both steel and other metals, and particularly aluminium, should never be exposed to sodium hydroxide. Where the instrument cannot tolerate the method, the Canadian path resolves to discard for confirmed cases and to quarantine for suspected cases, and the quarantine decision is not soft: a confirmed diagnosis other than CJD, either clinical or pathological, or a postmortem examination excluding CJD, is required to release the instruments, and a brain biopsy that is negative for CJD does not suffice on its own.
The rare exception is made explicit. For at-risk asymptomatic patients — recipients of human tissue-derived pituitary hormone treatment, recipients of a dura mater graft, recipients of a corneal graft from a jurisdiction that does not require donors to be screened for neurological disease, and patients exposed through instruments to high-infectivity tissue of a confirmed CJD patient — the working group concluded that the risk of transmission via instruments is negligibly low and recommended routine decontamination and reuse.
What does the Canadian decontamination method actually specify?
The Canadian method is a combined four-step sequence, not a single parameter:
- Clean thoroughly.
- Soak in 1 N sodium hydroxide for 1 hour.
- Rinse thoroughly.
- Sterilize in a prevacuum-method autoclave at 134 °C for 60 minutes.
Two substitutions are accepted for steps 2 and 4: 2 percent sodium hypochlorite at 20,000 parts per million available chlorine in place of the sodium hydroxide, and a prevacuum cycle at 134 °C for 18 minutes in place of 60 minutes.
The international annex lists a longer menu in descending order of severity, from incineration through gravity-displacement and porous-load autoclave combinations with sodium hydroxide or hypochlorite, down to autoclaving at 134 °C for 18 minutes as the least severe option, and it flags that in worse-case scenarios such as brain tissue bake-dried onto surfaces, infectivity is largely but not completely removed. It also specifies that sodium hydroxide working solutions should be prepared fresh because a 1 N solution reacts with carbon dioxide in air to form carbonates that neutralise it, and that hypochlorite efficacy depends on available chlorine rather than on a fixed dilution, since household and industrial bleach are sold at different concentrations.
How does the US position differ in practice?
The substantive methods are the same, because the CDC's three most stringent sterilization methods for heat-resistant instruments are drawn from the WHO annex. The differences are in framing and in two operational details.
| Point | Canada | United States |
|---|---|---|
| Primary control lever | Decide before the procedure where possible, and track instruments so a retrospective decision is still possible | Destroy heat-resistant instruments that contact high-infectivity tissue as the safest method, then fall back to the sterilization protocols |
| Handling during the procedure | Instruments kept moist until cleaned and decontaminated, then cleaned as soon as possible | Do not let instruments air dry during the surgical procedure; keep them moist in water or disinfectant solution |
| Unknown-status patients | Managed through the suspected-CJD branch of the decision path | Reprocess as if the patient has suspected or confirmed CJD unless the patient is diagnosed with a condition that is not CJD |
| Effect on instruments | Notes that stainless steel tolerates sodium hydroxide and that aluminium-containing instruments must not be exposed to it | Reports that a regulator evaluation found much of the damage from autoclaving in sodium hydroxide was cosmetic rather than functional, and that immersion in the bleach alternative caused severe damage to some instruments |
| Heat-sensitive items and surfaces | Handled through the same discard-or-decontaminate logic | Incinerate disposables; flood or soak surfaces and heat-sensitive reusable instruments in 2 N sodium hydroxide or undiluted sodium hypochlorite for 1 hour, then rinse |
Underneath both is the same historical argument for doing any of this at all. The CDC states that iatrogenic transmission of the CJD agent has been reported in more than 500 patients, mostly linked to contaminated human growth hormone and dura mater grafts, with further cases linked to corneal transplants, contaminated neurosurgical instruments and stereotactic EEG depth electrodes — and that no such transmission has been reported since 1976, when decontamination procedures were improved.
What records does the Canadian path assume a facility can produce?
The Canadian guidance is unusually explicit that the availability of records changes the outcome. Without detailed information about which reusable instruments contacted potentially infectious tissue, it says, the only way to eliminate all risk is to discard every potentially contaminated instrument, which creates considerable waste — and the opportunity to reduce the risk from instruments already back in circulation is lost. It therefore recommends limiting the number of instruments used, using disposable instruments wherever possible when high-infectivity tissue is involved, choosing reusable instruments that can tolerate CJD decontamination, and tracking instrument use. Three tracking measures are described in ascending order of effectiveness: identifying sets used only on brain, neuro and orthopaedic spine, and retina or posterior eye, and keeping them separate; identifying within a set the instruments used only on high-infectivity tissues; and identifying each individual instrument and the set it belongs to, with the record linked to the patients on whom it was used.
The provincial layer adds the notification floor. In Ontario, Creutzfeldt-Jakob disease is a designated communicable disease under the Health Protection and Promotion Act and its regulation, confirmed, probable and suspect cases are reportable, and the provincial case definitions list exposure to neurosurgical instruments used in a case of confirmed or probable human prion disease as a recognised iatrogenic risk factor alongside pituitary hormone treatment, dura mater grafts and corneal grafts from unscreened donors.
What this does not change is the daily monitoring that a Canadian clinic already runs. A biological indicator verifies that the sterilization cycle performed as intended; it does not demonstrate that a prion was inactivated, and the guidance above exists precisely because that gap is real. The two records sit side by side: the cycle record that a spore test supports, and the instrument traceability record that a CJD decision path depends on.
For the cycle record itself, a self-contained biological indicator is the item that carries the test, and the packaging carries the traceability that the guidance above assumes exists. A 5-pack trial of a self-contained steam indicator is enough to run a first week of daily verification on one sterilizer, and the Class 4 dual-indicator sterilization pouch assortment covers the packaging side where external indicators and a written load label are the only visible record on the pack. Care homes, laboratories and multi-site groups usually place those orders through the institutional account channel. Reselling? become a distributor.
Where to go next: the printable monitoring log and the digital compliance log at our sterilization compliance log centre cover the cycle side of that pair, and the instrument and load fields are designed to be filled in at the bench rather than reconstructed later.
Have a question about your own facility? Send it in and you will get a written answer specific to your setup, with the regulation or standard it is based on cited. Ask your compliance question.
Anything in this article describes published guidance only. Which decontamination method a specific instrument can survive is a question for the manufacturer's instructions for use, and which requirements bind a particular facility is a question for the provincial regulator.
Related reading
- Do autoclaves kill prions? What Canadian guidelines say
- ISO 15883-1:2024 washer-disinfectors: validation and routine testing requirements for Canadian facilities
- Critical vs semi-critical vs non-critical instruments: why the category decides reprocessing
- Instrument disassembly before cleaning: what comes apart and what stays together
The wider reference set for Canadian facilities sits in the sterilization compliance hub.
Frequently Asked Questions
Why are prions a special case in reprocessing?
Because the infectious agent is a misfolded protein rather than a living organism, the temperatures and contact times that reliably inactivate bacteria, fungi and viruses are not treated as dependable against it. Both the Canadian quick reference guide and United States guidance describe the recommended methods as conservative, and the Canadian document states it does not regard a prevacuum cycle at 134 °C for 18 minutes on its own as sufficient to deactivate prions.
Which tissues are classified as high infectivity in Canada?
Brain, dura mater, pituitary gland, posterior eye including the optic nerve and retina, spinal cord and spinal ganglia, and the trigeminal ganglia. Cerebrospinal fluid is classified as low infectivity but is managed as a high-infectivity tissue or fluid because contact with it necessarily implies contact with high-infectivity tissue.
Is the instrument itself classified as high risk?
No. In the Canadian decision path, risk comes from two inputs: whether the patient is a potential CJD transmitter, and the infectivity category of the tissue the instrument contacted. The instrument enters the decision only at the point where the guidance asks whether it can tolerate CJD decontamination — stainless steel generally can, instruments with plastic or electronic components such as bronchoscopes cannot, and instruments containing aluminium must not be exposed to sodium hydroxide at all.
What happens to instruments after a suspected CJD case?
Instruments that contacted high-infectivity tissue are routinely reprocessed separately and then quarantined. They cannot be returned to use unless a diagnosis is made that excludes CJD, which requires a confirmed alternative diagnosis, clinical or pathological, or a postmortem examination excluding CJD; a brain biopsy that is negative for CJD does not suffice on its own.
Does Canada and the United States use different decontamination methods?
The substantive methods are shared. The CDC lists its three most stringent sterilization methods for heat-resistant instruments with reference to the international annex, and the Canadian guide specifies a four-step sequence of cleaning, a one-hour soak in 1 N sodium hydroxide, a thorough rinse, and a prevacuum autoclave cycle at 134 °C for 60 minutes, with 2 percent sodium hypochlorite at 20,000 parts per million available chlorine and an 18-minute cycle accepted as substitutions. The differences are mostly in framing and in how unknown-status patients are routed.
Why does instrument tracking matter so much in this topic?
Because the Canadian guidance says so directly. Without detailed information about which reusable instruments contacted potentially infectious tissue, the only way to eliminate all risk is to discard every potentially contaminated instrument, and the chance to act on instruments already back in circulation is lost. Where instruments cannot be identified, the retrospective branch of the Canadian decision path turns on whether the instruments had already been reprocessed more than nine times.
Does a spore test tell me anything about prions?
It verifies that the sterilization cycle performed as intended against a defined biological challenge. It is not a prion test, and no routine biological monitoring programme demonstrates prion inactivation. The two are separate records kept for separate purposes.
Sources
- Classic Creutzfeldt-Jakob Disease in Canada: Quick Reference Guide 2007 — Public Health Agency of Canada
- Infection Control for CJD — Centers for Disease Control and Prevention
- About Prion Diseases — Centers for Disease Control and Prevention
- WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies (WHO/CDS/CSR/APH/2000.3) — World Health Organization
- Creutzfeldt-Jakob Disease, all types: case definitions and disease-specific information — Ontario Public Health Standards, Infectious Diseases Protocol, April 2026
- Creutzfeldt-Jakob disease protocol, acute care infection prevention and control manual — Winnipeg Regional Health Authority
- Classic Creutzfeldt-Jakob disease in Canada: infection control guideline — Government of Canada publications record for the 2002 guideline, Canada Communicable Disease Report supplement
CliniEco Medical supplies sterilization monitoring consumables and clinical consumables to Canadian dental clinics, long-term care homes, veterinary practices and laboratories. CliniEco Medical holds MDEL #35334.
0 comments